Literature DB >> 8650590

Clinical expression of rheumatoid arthritis in Chilean patients.

L Massardo1, V Aguirre, M E García, V Cervila, S Nicovani, A González, S Rivero, S Jacobelli.   

Abstract

In populations such as Northern Europeans in which the HLA-DR4 subtypes DW14 and Dw4 show strong association with rheumatoid arthritis (RA), these alleles and the double allelic dose of the shared epitope are considered severity markers. The clinical expression of RA varies in different populations, which may be determined by variation in the prevalence of these markers. In the present study we analyzed the expression of RA in 112 consecutive Chilean patients and its relation to the prevalence of genetic factors, prompted by our previous observation that DR4 is weakly associated to RA in this population. Mean age was 50 +/- 14 years; 90% were seropositive and 87% were female, with a disease duration of 10 +/- 8 years. Extra-articular manifestations were found in 38% of patients, rheumatoid nodules in 27%, vasculitis in 8%, and Sjogren's syndrome in 29%. Functional capacity (ACR, 1991) I or II: 82%.15% of patients stopped working. Hand radiographs scored according to Steinbrocker in 89 patients: I, 21%; II, 15%; III, 43%; IV, 21%. In this series, patients with less formal education seemed to have more benign arthritis. In 97 controls and in 65 (56%) RA patients the presence of DRB1 alleles corresponding to DR1 and DR4 serotypes, to DR4-Dw subtypes, and homozygocity, were determined by polymerase chain reaction followed by specific oligonucleotide hybridization. The shared epitope was present in 53% of RA patients and in 30% of controls (P = .0048, odds ratio [OR] = 2.64). A double allelic dose of the epitope was present in 15% of RA patients compared with 4% of controls (P = .026, OR = 4.23). In a subgroup of 31 erosive RA patients we did not find a significant association of disease severity with the shared epitope in a single or double allelic dose. None of the DR4 subtypes that associate with RA in other populations was found significantly more prevalent in our patients. The severity of RA in our study compared with published series was intermediate between British patients with severe RA and Greek patients with milder disease. This may be due to the high prevalence of Dwl3*0403 in our population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8650590     DOI: 10.1016/s0049-0172(95)80032-8

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  6 in total

1.  Prevalence of antiphospholipid antibodies in Chilean patients with rheumatoid arthritis.

Authors:  Iván Palomo; Carmen Pinochet; Marcelo Alarcón; Rodrigo Sandoval; Jaime Gonzalez; Francisco Monsalves; Ricardo Forastiero
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

2.  Lag time between onset of symptoms and diagnosis in Venezuelan patients with rheumatoid arthritis.

Authors:  Elaudi Rodríguez-Polanco; Soham Al Snih; Yong-Fang Kuo; Alberto Millán; Martín A Rodríguez
Journal:  Rheumatol Int       Date:  2010-01-12       Impact factor: 2.631

3.  Heavy burden of non-communicable diseases at early age and gender disparities in an adult population of Burkina Faso: World Health Survey.

Authors:  Malgorzata Miszkurka; Slim Haddad; Étienne V Langlois; Ellen E Freeman; Seni Kouanda; Maria Victoria Zunzunegui
Journal:  BMC Public Health       Date:  2012-01-10       Impact factor: 3.295

Review 4.  The epidemiology of Sjögren's syndrome.

Authors:  Ruchika Patel; Anupama Shahane
Journal:  Clin Epidemiol       Date:  2014-07-30       Impact factor: 4.790

Review 5.  Help-seeking trajectory in patients with rheumatoid arthritis.

Authors:  Ingris Pelaez; Claudia Infante; Rosana Quintana
Journal:  Clin Rheumatol       Date:  2015-07-23       Impact factor: 2.980

6.  Overlapping Sjogren's syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019.

Authors:  Huijuan Zhang; Haoze Zhang; Dai Gao; Wenhui Xie; Yan Geng; Zhuoli Zhang
Journal:  Arthritis Res Ther       Date:  2020-05-01       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.